 Relief Therapeutics Holding SAs OTC: RLFTF collaborating partner NRx Pharmaceuticals Inc NASDAQ: NRXP has announced that the FDA has denied Breakthrough Therapy Designation for aviptadil. NRx noted that though the designation is not required for drug approval or emergency use authorization, but can afford faster review times, the ability to submit a rolling application, and dedicated FDA review personnel. 